Treatment Sequencing Approaches for Patients With HER2+ mBC

Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.

Related Keywords

,Real World Evidence ,Sequencing Approaches ,Patients With ,Breast Cancer ,Metastatic Breast Cancer ,Her2 Metastatic Breast Cancer ,Her2 Positive Breast Cancer ,Advanced Her2 Positive ,Drug Approvals ,Thp ,T Dx1 ,Therapy Considerations ,Stable Brain Metastases ,Active Brain Metastases ,Her2climb 05 ,